Clinical Trial Detail

NCT ID NCT02316002
Title Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.